鍉圆针定量痧疗术对改善盐酸羟考酮治疗中重度癌性疼痛的疗效观察

目的 研究鍉圆针定量痧疗术对改善盐酸羟考酮治疗中重度癌性疼痛（癌痛）的疗效。方法 将收治的60例中重度癌痛患者按随机对照原则分为对照组和试验组各30例。对照组给予盐酸羟考酮治疗，试验组在对照组的基础上采用鍉圆针定量痧疗术治疗，比较两组临床疗效、不良反应及治疗前后疼痛程度、生活质量。结果 治疗后，试验组治疗总有效率（96.67%）高于对照组（83.33%）(P>0.05)；试验组疼痛数字评分法（NRS）评分低于对照组，生活质量评分表（KPS）评分高于对照组（P<0.05）；不良反应总发生率（20.00%）低于对照组（30.00%），但无统计学意义（P>0.05）。结论在盐酸羟考酮治疗中重度癌痛基础上增加鍉圆针定量痧疗术治疗可有效缓解患者癌痛症状，提升生活质量，疗效确切且安全性可。     

温经止痛方温敷改善老年肺癌骨转移患者中重度癌痛的效果观察

目的：探讨应用温经止痛方治疗老年肺癌骨转移患者中重度癌痛的效果。方法：选取2018年9月~2020年6月收治的78例老年非小细胞肺癌骨转移患者,采用随机数字表法分为对照组和观察组,每组39例。对照组采用盐酸羟考酮缓释片治疗,观察组采用盐酸羟考酮缓释片+温经止痛方温敷治疗,均连续治疗1周。比较两组疼痛评分、爆发痛次数、功能状态评分和生活质量评分、不良反应发生情况。结果：观察组治疗后疼痛评分、爆发痛次数、生活质量评分均低于对照组,功能状态评分高于对照组,差异有统计学意义（P＜0.05）;两组不良反应发生率比较,差异无统计学意义（P＞0.05）。结论：温经止痛方温敷治疗老年肺癌骨转移患者中重度癌痛,对于减轻疼痛、提高生活质量具有积极的作用,且不良反应较少,安全可靠。     

羟考酮缓释片、吗啡缓释片治疗重度癌痛的效果

目的:探究羟考酮缓释片、吗啡缓释片治疗重度癌痛的效果及对患者生活质量的影响。方法:采用随机数字法将2016年1月～2019年3月收治的重度癌痛患者78例分为羟考酮组与吗啡组,各39例,分别采用羟考酮缓释片、吗啡缓释片治疗。比较两组疼痛缓解总有效率、起效时间、不良反应发生情况及生活质量评分。结果:两组疼痛缓解率比较,差异无统计学意义(P0.05);羟考酮组起效时间短于吗啡组,便秘发生率低于吗啡组(P0.05);用药7 d后,两组生活质量评分均较用药前提高(P0.05),但两组用药后生活质量评分比较,差异无统计学意义(P0.05)。结论:羟考酮缓释片与吗啡缓释片缓解恶性肿瘤重度癌痛的疗效相当,但羟考酮缓释片起效更快,便秘等不良反应更轻微。     

观察盐酸羟考酮缓释片联合盐酸吗啡片滴定治疗中重度癌痛的效果及对睡眠质量的影响

目的：观察盐酸羟考酮缓释片联合盐酸吗啡片滴定治疗中重度癌痛的效果及对睡眠质量的影响。方法：选取2019年10月至2020年10月内蒙古科技大学包头医学院第二附属医院收治的中重度癌痛患者150例作为研究对象,按照随机数字表法分为观察组和对照组,每组75例。对照组给予盐酸吗啡片治疗,观察组给予盐酸羟考酮缓释片联合盐酸吗啡片治疗。比较2组患者睡眠时间的差异,同时比较2组患者的疼痛缓解情况及不良反应发生率。结果：治疗后,观察组的疼痛缓解情况显著优于对照组,观察组患者睡眠时间显著长于对照组,2组比较差异均有统计学意义(均P<0.05);观察组不良反应发生率与对照组比较,差异无统计学意义(P>0.05)。结论：盐酸羟考酮缓释片联合盐酸吗啡片滴定有助于缓解中重度癌痛患者的疼痛,可显著延长患者的睡眠时间,不增加不良反应发生率。     

盐酸羟考酮缓释片联合星状神经节阻滞治疗 癌痛患者80例

目的：研究盐酸羟考酮缓释片联合星状神经节阻滞对癌痛患者疼痛程度、自我效能感、免疫功能及 生活质量的影响。方法：癌痛患者80例随机分成药物组（盐酸羟考酮缓释片治疗）和联合组（盐酸羟考酮 缓释片联合星状神经节阻滞治疗），各40例。于治疗前、治疗后15 d及30 d，采用视觉模拟评分法（VAS）评 分评估疼痛，采用慢性疼痛自我效能感量表（CPSS）评价自我效能感，采用流式细胞仪检测外周血CD3+、 CD4+、CD8+、CDl6+ 56+ 数量，采用生活质量核心量表（QOL）-30评估生活质量，并比较不同时间点盐酸羟考 酮使用量。结果：治疗后 30 d，联合组 VAS 评分低于药物组（P＜0.05），CPSS 各分量表评分高于药物组 （P＜0.05），QOL-30评分高于药物组（P＜0.05）；治疗后15 d及30 d，联合组CD3+、CD4+、CDl6+ 56+ 细胞比例 高于药物组（P＜0.05），CD8+ 细胞比例低于药物组（P＜0.05）；各时间点联合组羟考酮使用量均低于药物组 （P＜0.05）。结论：盐酸羟考酮缓释片联合星状神经节阻滞治疗癌痛，能显著提升疗效、减少羟考酮使用 量、改善患者免疫功能及生活质量，提升自我效能感。     

盐酸羟考酮控释片治疗带状疱疹后神经痛的临床研究

目的研究盐酸羟考酮控释片治疗带状疱疹后神经痛的有效性及安全性。方法比较分析40例带状疱疹后神经痛患者经盐酸羟考酮控释片治疗后疼痛强度、生活质量等变化。疼痛强度采用数字分级法（MRS）评定。结果40例患者治疗前NRS评分（9．13±0．65）分,治疗后NRS评分（3．00±0．36）分,与治疗前相比差异有显著性（P〈0．05）。其中疼痛消失31例,显效6例,有效3例,有效率达100％。治疗后患者生活质量均得到改善。结论盐酸羟考酮控释片是治疗带状疱疹后神经痛的有效及安全的药物之一。     

氨酚羟考酮片与盐酸羟考酮缓释片治疗中重度癌痛的对比

目的探讨盐酸羟考酮缓释片治疗中重度癌痛的临床价值。方法选择2010年1月至2013年6月晚期恶性肿瘤患者80例,按随机数字表法分为两组,各40例。对照组使用氨酚羟考酮片5 mg,口服,每12小时1次,每次1片;观察组使用盐酸羟考酮缓释片每日晨服10 mg,每12小时1次,每次1片。比较两组患者治疗后不良反应以及治疗后24 h疼痛VAS评分。结果观察组胃肠道不适、循环抑制、呼吸抑制及头晕的发生率均显著低于对照组(P<0.01或P<0.05),观察组从用药后4 h开始,其疼痛VAS评分即显著低于对照组(P均<0.01)。结论盐酸羟考酮缓释片治疗中重度癌痛,临床作用时间较持久,且不良反应更少,整体效果优于氨酚羟考酮片。     

盐酸羟考酮控释片治疗中重度癌痛的临床观察

目的观察盐酸羟考酮控释片（奥施康定）治疗中重度癌痛的疗效。方法选择52例中重度癌痛患者进行治疗，观察起效时间、治疗效果以及不良反应。结果盐酸羟考酮控释片治疗中重度癌痛起效快，平均起效时间为37min（25～65min），平均镇痛时间为10．8h（8～14h）。镇痛效果明显，总缓解率为96．2％。不良反应有便秘、恶心、呕吐、头晕、嗜睡、多汗和一过性排尿困难。结论盐酸羟考酮控释片可以安全用于中重度癌痛患者的止痛治疗。     

盐酸羟考酮缓释片治疗中重度癌痛患者的临床效果及对其生活质量的影响

目的探讨盐酸羟考酮缓释片治疗中重度癌痛患者的临床效果及对其生活质量的影响。方法选取我院2018年10月至2019年9月收治的64例中重度癌痛患者作为研究对象,采用随机数字法将其分为参照组(32例,盐酸吗啡片)和治疗组(32例,盐酸羟考酮缓释片)。比较两组患者的癌痛缓解情况、生命质量和身体情况。结果治疗1、6、12、24、48 h,治疗组的癌痛缓解有效率均明显高于参照组,差异具有统计学意义(P<0.05)。治疗后,治疗组生命质量测定量表EORTC QLQ-C30功能领域、总体健康状况领域评分明显高于治疗前与参照组(P<0.05),症状领域评分明显低于治疗前与参照组,差异具有统计学意义(P<0.05)。治疗后,治疗组美国东部肿瘤协作组体能状态(ECOG-PS)评分明显低于治疗前与参照组,差异具有统计学意义(P<0.05)。结论盐酸羟考酮缓释片治疗中重度癌痛的临床效果显著,可提高患者的生活质量,值得临床推广应用。     

氟伏沙明联合羟考酮缓释片治疗中重度癌痛120例临床护理

目的:探讨氟伏沙明联合羟考酮缓释片治疗中重度癌痛的临床效果及护理方法。方法:将240例中重度癌痛患者随机分为观察组和对照组120例,观察组采用氟伏沙明联合羟考酮缓释片控制癌痛,对照组单用羟考酮缓释片控制癌痛,采用健康宣教、疼痛评估、舒适护理、心理护理及不良反应的观察护理等措施,比较两组效果。结果:观察组较对照组疼痛明显减轻(P0.05),生活质量评分较对照组明显提高(P0.05),便秘发生率低于对照组(P0.05)。结论:氟伏沙明联合羟考酮缓释片,配合相应的护理措施,可以有效控制中重度癌痛,改善生活质量。     

不同途径应用盐酸羟考酮控释片治疗中重度癌性疼痛临床效果观察

目的：观察应用盐酸羟考酮控释片（TM）口服和经直肠不同途径给药对中重度癌性疼痛的疗效和不良反应。方法：61例伴有中重度疼痛的癌症患者随机分A组（口服TM）31例和B组（经直肠应用TM）30例。分别应用≤60mg／d和〉60mg／d两个剂量组，对TM的不同程度疼痛的疗效和不良反应进行观察。结果：A组患者维持剂量≤60mg／d和〉60mg／d的有效率分别为83．3％、85．7%，而B组患者分别为81．8％、87．5％，两组无明显差异（P〉0．05）；并且进一步对A、B两组不同的疼痛分级、不同的疼痛类型的止痛效果分析，均无统计学差异（P〉0．05）；另外，A、B两组的不良反应如恶心、呕吐、便秘、排尿困难、嗜睡等均无统计学差异（P〉0．05）。结论：经口服和直肠应用TM的疗效和不良反应相近，对重症且进食、进水、吞咽困难者或肠道肿瘤致肠梗阻者经直肠应用TM是有效、安全、方便的镇痛方法之一。     

羟考酮控释片（奥施康定）缓解癌痛及改善肺癌患者生活质量的观察

目的：评价羟考酮控释片在治疗慢性癌痛中的疗效及安全性。同时观察伴随疼痛的肺癌患者在接受奥施康定镇痛治疗后其生活质量的改善情况。方法：疼痛的评价采用0-10数字疼痛强度评分法，并记录剂量滴定达稳态时间和维持剂量。采用生活质量量表EORT CQLQ-C30（V3．0）中文版对其中28名肺癌患者治疗前后的生活质量进行了评估。结果：入组的48例患者中，有46例可评价疗效及安全性。其中42例（87．5％）患者达到了满意的疼痛缓解，平均滴定达稳态时间为2．1天。用药期间，25名（52．1％）患者曾经发生至少1种不良反应。在疼痛缓解的同时，大多数肺癌患者的生活质量得到了改善。结论：奥施康定用于治疗中重度癌性疼痛是安全有效的；它能改善肺癌疼痛病人的生活质量。     

Oxycodone hydrochloride controlled-release tablets (OxyContin®): post-marketing surveillance (PMS) study for relieving moderate to severe non-cancer pain

ObjectiveTo evaluate the efficacy and safety of oxycodone hydrochloride controlled-release (CR) tablets (Oxycontin®, Mundipharma International Limited, Cambridge, UK), 5 mg, 10 mg, 20 mg, and 40 mg in relieving moderate to severe non-cancer pain.MethodTwo multi-center, open-label, prospective, self-controlled clinical trial, used identical protocols. All the subjects were patients with moderate to severe non-cancer pain. The clinical data were collected in the natural course of clinical treatment.ResultsTreatments with oxycodone CR tablets was associated with fast onset on pain relief; 85.2% of patients in study 1 and 91.8% of patients in study 2 achieved pain relief within 1 hour of drug administration.Clinical efficacyBoth studies demonstrated that oxycodone CR tablets showed good clinical efficacy for relieving both moderate and severe non-cancer pain. Patients experienced sustained pain relief from the first week of treatment. Patients in both study 1 and study 2 experienced a dramatic pain score reduction (as assessed by VAS) after the first week of treatment.Safety profileDuring oxycodone CR treatment, use of concomitant medications decreased significantly. A few patients developed ADRs in the first week, which decreased significantly as the treatment continued. Constipation was the most common ADR in the first week, which decreased to 10% of patients from the second week of treatment.ConclusionOxycodone CR tablets demonstrated fast onset of pain control and superior efficacy for relieving both moderate and severe non-cancer pain, as well as significant reductions in the number of concomitant medications, demonstrating a good safety profile.     

Therapie chronischer Schmerzen mit oralem retardiertem Oxycodon

Oral controlled-release oxycodone has been available for the treatment of chronic pain in Germany since 1998. Controlled trials have shown good clinical efficacy and tolerability. This survey reports results from six open prospective multicenter trials. In these trials 4196 patients suffering from cancer pain and non-cancer-related pain with inadequate pain relief were treated with oral controlled-release oxycodone for 3-4 weeks. Only a few participating physicians were pain specialists. A total of 356 patients suffering from pain of the musculoskeletal system and receiving oxycodone therapy were monitored for 6 months. Exclusion from the studies was due mainly to inadequate analgesia, side effects, and noncompliance. The efficacy of oxycodone was rated to be better than moderate by most of the patients, quality of life parameters increased significantly, and patient satisfaction was high. The treatment with oral controlled-release oxycodone was a safe and effective option even when used by nonspecialized physicians.     

Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study.

Controlled-release oral formulations of oxycodone and morphine are both suitable analgesics for moderate to severe pain. They were compared in cancer-pain patients randomized to double-blind treatment with controlled-release oxycodone (n = 48) or controlled-release morphine (n = 52) every 12 h for up to 12 days. Stable analgesia was achieved by 83% of controlled-release oxycodone and 81% of controlled-release morphine patients in 2 days (median). Following titration to stable analgesia, pain intensity (0=none to 3=severe) decreased from baseline within each group (p 相似文献   

Controlled-release oxycodone for the treatment of bortezomib-induced neuropathic pain in patients with multiple myeloma

Purpose

Bortezomib, a proteasome inhibitor drug very effective against multiple myeloma, may induce the so-called bortezomib-induced peripheral neuropathy (BIPN), hardly manageable with common analgesic drugs. This study assessed the effectiveness of controlled-release (CR) oral oxycodone in controlling pain and its interference on daily functions of patients with hematologic malignancies affected by BIPN.

Methods

Forty-six patients (median age, 62 years) affected by myeloma and lymphoma, complaining of BIPN-related pain of moderate-to-severe intensity and unresponsive to previous analgesic treatments, were treated with CR oxycodone. The intensity of continuous and brief pain (BP) along with interference of pain with the common daily dimensions of feeling and function were evaluated by using an 11-point numerical rating scale (NRS); a global patient evaluation of efficacy was also performed.

Results

The daily average dose of CR oxycodone administered was 28.46 mg (range, 20–80 mg). The pain intensity decreased from a mean NRS value of 7.6 at baseline to 1.3 on day 14. The frequency of BP was reduced from 61 to 47 % of patients and its intensity from 7.4 to 3.1 NRS score. A similar trend to decreasing values was observed for all the daily life functions. Slight- or mild-intensity side effects were observed in 23 patients (51 %). At the end of the study, 75 % of patients found the treatment effective or very effective.

Conclusion

CR oxycodone for relief of BIPN-related pain was effective and well tolerated. The pain control significantly improved also the quality of the daily life functions, which are usually compromised in these suffering patients.     

氨酚羟考酮和曲马多用于骨科上肢手术患者术后镇痛的疗效观察

[目的]评价口服氨酚羟考酮用于骨科上肢手术患者术后镇痛的有效性和安全性.[方法]对90例骨科上肢手术行臂丛麻醉的患者随机分三组,即氨酚羟考酮组(A组)、曲马多(B组)和安慰剂(维生素C)组(C组),每组30例,三组患者均于术毕时口服第一片,当日为每6 h服1片,直至入睡,最多3片;后每次1片,3次/日,再连续服用2 d...     

Treatment of persistent pain associated with osteoarthritis with controlled-release oxycodone tablets in a randomized controlled clinical trial

OBJECTIVE: This study, lasting up to 90 days, was undertaken in patients with osteoarthritis with persistent moderate to severe pain uncontrolled by standard therapy (nonsteroidal anti-inflammatory drugs, acetaminophen, and/or short-acting opioids) to evaluate functional outcomes, as well as efficacy and safety, of controlled-release oxycodone versus placebo. METHODS: One hundred seven patients received either controlled-release oxycodone or placebo every 12 hours in this double blind, randomized, placebo-controlled, parallel-group study. Stable previous regimens of acetaminophen or nonsteroidal anti-inflammatory agents were allowed to continue. Primary efficacy variables included Brief Pain Inventory average pain intensity scores at completion of initial titration, Western Ontario and McMaster Universities Osteoarthritis Index scores at days 30 and 60, and the percentage of patients discontinuing due to inadequate pain control. RESULTS: Controlled-release oxycodone was significantly superior to placebo in decreasing average pain intensity and in reducing pain-induced interference with general activity, walking ability (except at day 30), and normal work, as well as mood, sleep, relations with people (at days 60 and 90), and enjoyment in life. Daily functioning, as measured by the Western Ontario and McMaster Universities Osteoarthritis Index, was also significantly improved in the controlled-release oxycodone group. In the placebo group, a significantly greater percentage of patients discontinued due to inadequate pain control. Adverse events were consistent with opioid adverse events, and no safety concerns were noted. DISCUSSION: Treatment with controlled-release oxycodone of patients with osteoarthritis with persistent moderate to severe pain uncontrolled by standard therapy resulted in significant pain control and improvements in physical functioning.     

Analgesic efficacy of controlled-release oxycodone in patients with uterine or ovarian cancer

Treatment with opioid analgesics often causes adverse reactions that may make continuous use of such drugs difficult. We investigated the efficacy and safety of controlled-release oxycodone in the treatment of gynecologic cancer pain. The patients included 14 with cervical cancer, 6 with corpus cancer, and 17 with ovarian cancer. Treatment with controlled-release oxycodone was started at 5 mg/dose when pain control using nonsteroidal anti-inflammatory drugs became ineffective. The dose was titrated to the optimal level over a mean duration of 2.34 +/- 1.13 days, and the initially optimal dose was 18.92 +/- 5.23 mg/day. Although no patients experienced confusion, vomiting, or respiratory depression, 17 patients experienced adverse events, including constipation in 14 patients and nausea in 9 patients. The incidence of nausea was low in patients receiving oxycodone and prochlorperazine. In the present study, patients with moderate to severe pain caused by gynecologic cancer could successfully be treated with controlled-release oxycodone.